Fulcrum Therapeutics, Inc. (FULC) Revenue History
Annual and quarterly revenue from 2017 to present
FULC Revenue Over Time (2017–2025)
FULC Revenue Growth History
2 of 5 years with positive growth- FY2017 revenue growth
- N/A
- FY2018 revenue growth
- N/A
- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- +117.2%
- FY2022 revenue growth
- -66.9%
- FY2023 revenue growth
- -55.8%
- FY2024 revenue growth
- +2752.0%
- FY2025 revenue growth
- -100.0%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $0 | — |
| Q4 2025 | $0 | — |
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | -100.0% |
| Q1 2025 | $0 | — |
| Q4 2024 | $0 | -100.0% |
| Q3 2024 | $0 | -100.0% |
| Q2 2024 | $80.0M | +8990.9% |
Multi-year avg. share of annual revenue by fiscal quarter
FULC Revenue Analysis (2017–2025)
Current Revenue & Growth
As of June 22, 2026, Fulcrum Therapeutics, Inc. (FULC) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue
Historical Growth Trajectory
FULC's historical revenue data shows various trends over time. Fulcrum Therapeutics, Inc.'s highest annual revenue of $80.0 million was recorded in 2024.
Peer Comparison
Compared to Healthcare sector peers — including ARWR (+14.1% YoY), SRPT (-2.2% YoY), and FOLD (+20.0% YoY). Compare FULC vs ARWR →
FULC Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| FULCCurrent | $0 | - | - | - | |
 ARWR | $829M | +14.1% | +56.6% | 11.9% | |
 SRPT | $2.2B | -2.2% | +32.4% | -29.9% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 CRSP | $4M | -88.9% | +37.3% | -16191.4% |
FULC Historical Revenue Data (2017–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | -100.0% | $-1,390,000 | - | $-84,769,000 | - |
| 2024 | $80.0M | +2752.0% | $16.6M | 20.8% | $-21,897,000 | -27.4% |
| 2023 | $2.8M | -55.8% | $2.8M | 100.0% | $-110,664,000 | -3945.2% |
| 2022 | $6.3M | -66.9% | $-70,440,000 | -1110.7% | $-112,561,000 | -1774.9% |
| 2021 | $19.2M | +117.2% | $-50,538,000 | -263.7% | $-81,054,000 | -423.0% |
| 2020 | $8.8M | - | $-50,219,000 | -569.2% | $-71,611,000 | -811.6% |
| 2019 | $0 | - | $-2,053,000 | - | $-58,626,000 | - |
| 2018 | $0 | - | $-1,345,000 | - | $-33,498,000 | - |
| 2017 | $0 | - | $-715,000 | - | $-22,993,000 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
9+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
FULC — Frequently Asked Questions
Quick answers to the most common questions about buying FULC stock.
Is FULC's revenue growth accelerating or slowing?
FULC TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is FULC's revenue history from 2017 to 2026?
Fulcrum Therapeutics, Inc. (FULC) revenue history spans 2017 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is FULC's long-term revenue growth rate (CAGR)?
Fulcrum Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for FULC.
Why does FULC's quarterly revenue fluctuate?
FULC quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Fulcrum Therapeutics, Inc.'s revenue data from 2017 to 2026 shows full historical quarterly detail on this page.
How is FULC's revenue distributed by segment?
FULC reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does FULC's revenue compare to industry peers?
Fulcrum Therapeutics, Inc. (FULC) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.